慢性静脉功能不全相关淋巴水肿的临床和经济影响，以及静脉干预后持续性水肿的发生率。
The clinical and economic impact of chronic venous insufficiency-associated lymphedema and the prevalence of persistent edema after venous intervention.
机构信息
Division of Interventional Radiology, Department of Radiology, Northwestern University, Chicago, IL, USA.
Department of Surgery, Stony Brook University Medical Centre, New York, NY, USA.
出版信息
Phlebology. 2024 Jun;39(5):353-358. doi: 10.1177/02683555241233355. Epub 2024 Feb 12.
OBJECTIVES
To determine the demographics, outcomes, and healthcare utilization of patients with chronic venous insufficiency-associated lymphedema (CVI-LED) and the prevalence of lymphedema-specific therapy use after venous intervention.
METHODS
The IBM MarketScan Commercial and Medicare Claims Databases were examined for patients with CVI-LED. Patient demographics and the use of lymphedema-specific therapy before and after venous intervention were collected.
RESULTS
Of 85,601 LED patients identified, 8,406 also had a diagnosis of CVI. In the CVI-LED group, 1051 underwent endovenous ablation or venous stent placement. The use of lymphedema-specific therapy before and after venous intervention was 52% and 39%, respectively ( < .05). The mean time of initiation of LED-specific therapy following venous intervention was 265 days after ablation and 347 days after stent placement.
CONCLUSION
Treating venous hypertension improves certain venous-related signs and symptoms of CVI. However, a significant proportion of patients have persistent edema which may reflect underlying, sub-optimally treated LED.
目的
确定慢性静脉功能不全相关淋巴水肿（CVI-LED）患者的人口统计学特征、结局和医疗保健利用情况，以及静脉干预后淋巴水肿特定疗法的使用情况。
方法
研究人员对 IBM MarketScan 商业和医疗保险索赔数据库中的 CVI-LED 患者进行了检查。收集了患者的人口统计学特征以及静脉干预前后淋巴水肿特定疗法的使用情况。
结果
在 85601 名 LED 患者中，有 8406 名患者还被诊断患有 CVI。在 CVI-LED 组中，有 1051 名患者接受了静脉内消融或静脉支架置入术。静脉干预前后淋巴水肿特定疗法的使用率分别为 52%和 39%（<0.05）。静脉内消融后，开始进行 LED 特定疗法的平均时间为 265 天，支架置入后为 347 天。
结论
治疗静脉高压可改善 CVI 的某些静脉相关体征和症状。然而，相当一部分患者仍存在持续性水肿，这可能反映了潜在的、治疗效果不理想的 LED。
Zotero 插件